Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 22

1.

Hypofractionated radiation therapy versus chemotherapy with temozolomide in patients affected by RPA class V and VI glioblastoma: a randomized phase II trial.

Pedretti S, Masini L, Turco E, Triggiani L, Krengli M, Meduri B, Pirtoli L, Borghetti P, Pegurri L, Riva N, Gatta R, Fusco V, Scoccianti S, Bruni A, Ricardi U, Santoni R, Magrini SM, Buglione M.

J Neurooncol. 2019 May 4. doi: 10.1007/s11060-019-03175-2. [Epub ahead of print]

PMID:
31054101
2.

Grading of Neuroendocrine Carcinomas: Correlation of 68Ga-PET/CT Scan with Tissue Biomarkers.

Liverani C, Bongiovanni A, Mercatali L, Foca F, Pieri F, De Vita A, Spadazzi C, Miserocchi G, Recine F, Riva N, Nicolini S, Severi S, Martinelli G, Ibrahim T.

Dis Markers. 2018 Dec 2;2018:6878409. doi: 10.1155/2018/6878409. eCollection 2018.

3.

Metastatic neuroendocrine neoplasia treatments in patients over 70 years of age.

Bongiovanni A, Recine F, Foca F, Fausti V, Riva N, Fabbri G, Severi S, Liverani C, De Vita A, Spadazzi C, Miserocchi G, Mercatali L, Amadori D, Ibrahim T.

Endocr Connect. 2018 Dec 1. pii: EC-18-0478.R1. doi: 10.1530/EC-18-0478. [Epub ahead of print]

4.

Characterization and Drug Sensitivity of a New High-Grade Myxofibrosarcoma Cell Line.

Miserocchi G, De Vita A, Mercatali L, Recine F, Liverani C, Spadazzi C, Pieri F, Riva N, Bongiovanni A, Casadei R, Fausti V, Ibrahim T.

Cells. 2018 Oct 25;7(11). pii: E186. doi: 10.3390/cells7110186.

5.

Myxofibrosarcoma primary cultures: molecular and pharmacological profile.

De Vita A, Recine F, Mercatali L, Miserocchi G, Liverani C, Spadazzi C, Casadei R, Bongiovanni A, Pieri F, Riva N, Amadori D, Ibrahim T.

Ther Adv Med Oncol. 2017 Dec;9(12):755-767. doi: 10.1177/1758834017737472. Epub 2017 Oct 28.

6.

Primary Culture of Undifferentiated Pleomorphic Sarcoma: Molecular Characterization and Response to Anticancer Agents.

De Vita A, Recine F, Mercatali L, Miserocchi G, Spadazzi C, Liverani C, Bongiovanni A, Pieri F, Casadei R, Riva N, Fausti V, Amadori D, Ibrahim T.

Int J Mol Sci. 2017 Dec 8;18(12). pii: E2662. doi: 10.3390/ijms18122662.

7.

Primary leiomyosarcoma of the bone: a case report and a review of the literature.

Recine F, Bongiovanni A, Casadei R, Pieri F, Riva N, De Vita A, Mercatali L, Liverani C, Spadazzi C, Miserocchi G, Fausti V, Amadori D, Ibrahim T.

Medicine (Baltimore). 2017 Nov;96(45):e8545. doi: 10.1097/MD.0000000000008545. Review.

8.

Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors.

Berardi R, Torniai M, Pusceddu S, Spada F, Ibrahim T, Brizzi MP, Antonuzzo L, Ferolla P, Panzuto F, Silvestris N, Partelli S, Ferretti B, Freddari F, Gucciardino C, Testa E, Concas L, Murgioni S, Bongiovanni A, Zichi C, Riva N, Rinzivillo M, Brunetti O, Giustini L, Di Costanzo F, Delle Fave G, Fazio N, De Braud F, Falconi M, Cascinu S.

Cancer Med. 2017 Jul;6(7):1493-1499. doi: 10.1002/cam4.1028. Epub 2017 May 25.

9.

Update on the role of trabectedin in the treatment of intractable soft tissue sarcomas.

Recine F, Bongiovanni A, Riva N, Fausti V, De Vita A, Mercatali L, Liverani C, Miserocchi G, Amadori D, Ibrahim T.

Onco Targets Ther. 2017 Feb 23;10:1155-1164. doi: 10.2147/OTT.S127955. eCollection 2017. Review.

10.

CORRECTION: Innovative approaches to establish and characterize primary cultures: an ex vivo 3D system and the zebrafish model.

Liverani C, La Manna F, Groenewoud A, Mercatali L, Van Der Pluijm G, Pieri F, Cavaliere D, De Vita A, Spadazzi C, Miserocchi G, Bongiovanni A, Recine F, Riva N, Amadori D, Tasciotti E, Snaar-Jagalska E, Ibrahim T.

Biol Open. 2017 Feb 15;6(2):309. doi: 10.1242/bio.023911. No abstract available.

11.

Outcome Analysis of First-line Somatostatin Analog Treatment in Metastatic Pulmonary Neuroendocrine Tumors and Prognostic Significance of 18FDG-PET/CT.

Bongiovanni A, Recine F, Riva N, Foca F, Liverani C, Mercatali L, Nicolini S, Pieri F, Amadori D, Ibrahim T.

Clin Lung Cancer. 2017 Jul;18(4):415-420. doi: 10.1016/j.cllc.2016.11.004. Epub 2016 Nov 21.

PMID:
27956089
12.

Innovative approaches to establish and characterize primary cultures: an ex vivo 3D system and the zebrafish model.

Liverani C, La Manna F, Groenewoud A, Mercatali L, Van Der Pluijm G, Pieri F, Cavaliere D, De Vita A, Spadazzi C, Miserocchi G, Bongiovanni A, Recine F, Riva N, Amadori D, Tasciotti E, Snaar-Jagalska E, Ibrahim T.

Biol Open. 2017 Feb 15;6(2):133-140. doi: 10.1242/bio.022483. Erratum in: Biol Open. 2017 Feb 15;6(2):309.

13.

Current classification, treatment options, and new perspectives in the management of adipocytic sarcomas.

De Vita A, Mercatali L, Recine F, Pieri F, Riva N, Bongiovanni A, Liverani C, Spadazzi C, Miserocchi G, Amadori D, Ibrahim T.

Onco Targets Ther. 2016 Oct 11;9:6233-6246. eCollection 2016. Review.

14.

RANKL: A promising circulating marker for bone metastasis response.

Ibrahim T, Ricci M, Scarpi E, Bongiovanni A, Ricci R, Riva N, Liverani C, De Vita A, La Manna F, Oboldi D, Serra P, Foca F, Cecconetto L, Amadori D, Mercatali L.

Oncol Lett. 2016 Oct;12(4):2970-2975. Epub 2016 Aug 8.

15.

Recombinant granulocyte colony-stimulating factor (rG-CSF) in the management of neutropenia induced by anthracyclines and ifosfamide in patients with soft tissue sarcomas (NEUSAR).

Bongiovanni A, Monti M, Foca F, Recine F, Riva N, Di Iorio V, Liverani C, De Vita A, Miserocchi G, Mercatali L, Amadori D, Ibrahim T.

Support Care Cancer. 2017 Jan;25(1):111-117. Epub 2016 Aug 27.

PMID:
27568305
16.

Long-lasting activity of trabectedin in refractory uterine leiomyosarcoma: a case report.

Bongiovanni A, Riva N, Ricci M, Mercatali L, Liverani C, La Manna F, De Vita A, Cavaliere D, Pieri F, Oboldi D, Verdecchia GM, Amadori D, Ibrahim T.

BMC Cancer. 2015 Dec 22;15:998. doi: 10.1186/s12885-015-2038-7.

17.

First-line chemotherapy in patients with metastatic gastroenteropancreatic neuroendocrine carcinoma.

Bongiovanni A, Riva N, Ricci M, Liverani C, La Manna F, De Vita A, Foca F, Mercatali L, Severi S, Amadori D, Ibrahim T.

Onco Targets Ther. 2015 Dec 3;8:3613-9. doi: 10.2147/OTT.S91971. eCollection 2015.

18.

Pleural effusion in a patient with metastatic gastrointestinal stromal tumor treated with imatinib: case report.

Bongiovanni A, Ricci M, Riva N, Calpona S, Oboldi D, Pieri F, Cavaliere D, Mercatali L, Liverani C, La Manna F, De Vita A, Foca F, Gunelli E, Amadori D, Ibrahim T.

Future Oncol. 2014 Dec;10(15):2423-7. doi: 10.2217/fon.14.159.

PMID:
25525851
19.

Metronomic capecitabine in gastroenteropancreatic neuroendrocrine tumors: a suitable regimen and review of the literature.

Bongiovanni A, Riva N, Calpona S, Ricci M, Gunelli E, Liverani C, La Manna F, De Vita A, Monti M, Severi S, Pieri F, Amadori E, Galassi R, Cavaliere D, Zaccaroni A, Tartaglia A, Lunedei V, Gardini A, Mercatali L, Amadori D, Ibrahim T.

Onco Targets Ther. 2014 Oct 20;7:1919-26. doi: 10.2147/OTT.S68573. eCollection 2014.

20.

Single bone metastasis from adenocarcinoma of the lacrimal gland: a case report.

Ricci M, Amadori E, Chiesa F, Bongiovanni A, Liverani C, Fabbri L, Falasconi MC, Casadei R, Oboldi D, Galassi R, Micheletti S, Severi S, Serra L, Pieri F, Calabrese L, Riva N, Calpona S, Gunelli E, Mercatali L, Amadori D, Ibrahim T.

Future Oncol. 2014 Aug;10(10):1735-9. doi: 10.2217/fon.14.36.

PMID:
25303054

Supplemental Content

Loading ...
Support Center